EP300 and colorectal carcinoma: Vimentin expression will be suppressed by CRISPR approaches in butyrate‐resistant, p300‐deficient CRC cells (e.g. HCT‐R cells) and SW620 metastatic CRC cells; whereas vimentin will be overexpressed in butyrate‐sensitive cells (e.g. HCT‐116, LT97 microadenoma cells).